We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Memphis to House New Biological Reagents R&D and Manufacturing Center

By LabMedica International staff writers
Posted on 23 Aug 2010
A major supplier of biological reagents to the biotech and life science community has announced an ambitious plan for additional investments into facilities, equipment, and infrastructure to support research and development (R&D) and contract manufacturing activities.

Meridian Life Science, Inc. More...
(Cincinnati, OH, USA) cited increased demand for contract R&D and biological reagent manufacturing as the motivating factors behind the renovation and expansion scheme, which follows the 2009 investment that resulted in an additional cleanroom biomanufacturing suite, a sterility suite, and a pilot production laboratory.

The new facility will be located in Memphis, TN, USA, where it will consolidate all current R&D laboratories in a centralized R&D center. Other areas of the facility will be available for construction of up to five contract manufacturing, cell culture, and purification laboratories designed to support increased demand for contract manufacturing of monoclonal antibodies, viral antigens, and recombinant proteins.

The R&D center and the contract manufacturing laboratories will be equipped with state of the art systems for cell culture and protein purification. Also included in the expansion plan is the construction of a molecular biology laboratory with RT-PCR capabilities and an expanded quality control laboratory for testing incoming and outgoing materials.

Dr. Lourdes Weltzien, general manager of the Meridian Life Science Memphis Facility, said, "This recent round of expansion is necessary to provide the level and quality of contract manufacturing support our customers expect and require for their custom and critical biological reagents. We are excited and committed to increasing our capacity to service our customers, who can benefit from our core competence in cell culture, protein production, and purification. This recent expansion reaffirms our commitment as a leader in contract R&D and biologics manufacturing."

Related Links:
Meridian Life Science, Inc.


Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Blood Ammonia Test Analyzer
DRI-CHEM NX10N
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.